Preview the new medications of 2022, as we reach the halfway point of the year.
The U.S. Food and Drug Administration (FDA) is constantly reviewing and approving new medications and the number of medications approved in recent years, has drastically increased. Keeping up with all the changes can be a full-time job. In this post, we look at the most recent approvals to keep you informed and help you keep your patients safe.
How do you keep your staff informed and prepared to perform medication reconciliation? Medication reconciliation is not only a standard of practice, it’s an expectation of the licensing and accrediting organizations such as the Centers for Medicare and Medicaid Services (CMS), Accreditation Association for Ambulatory Health Care (AAAHC), The American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF) and The Joint Commission (TJC),
It’s imperative that medication reconciliation be comprehensive and consistent. When patients present their most current medication list, how often do you know every medication on the list? With the speed of new medication approvals, there’s no shame in admitting that sometimes you have to look it up. When the FDA approves new products, it often leads to additional treatment options for providers and patients alike, but it does make the reconciliation process more difficult.
Because the medication reconciliation process is so critical to patient safety, each year we provide our clients with a reference tool of the newest medications on the market. This tool serves multiple purposes, it educates, it helps with medication reconciliation and is a great reference for all staff members. As you’d expect, we will provide the complete tool at the end of the year. In the meantime, below is a simple list of the medications the FDA has approved so far this year and their use (Current as of June 14, 2022).
| Medication | Use |
| Quviviq | To treat insomnia |
| Cibinqo | To treat refractory, moderate-to-severe atopic dermatitis |
| Kimmtrak | To treat unresectable or metastatic uveal melanoma |
| Vabysmo | To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema |
| Enjaymo | To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease |
| Pyrukynd | To treat hemolytic anemia in pyruvate kinase deficiency |
| Vonjo | To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets |
| Ztalmy | To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder |
| Opdualag | To treat unresectable or metastatic melanoma |
| Pluvicto | To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies |
| Vivjoa | To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential |
| Camzyos | To treat certain classes of obstructive hypertrophic cardiomyopathy |
| Voquezna | To treat Helicobacter pylori infection |
| Mounjaro | To improve blood sugar control in diabetes |
| Vtama | To treat plaque psoriasis |
| Amvuttra | To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis |
For complete information on each of these medications, please refer to the FDA website and the FDA-Approved Prescribing Information. If you have questions or would like a copy of our reference tool, please reach out to us for more information.
The Consultant Pharmacists at OctariusRx provide guidance on safe medication management, survey readiness and cost savings to ambulatory healthcare facilities/surgery centers, senior care facilities and pharmacies. We also help individual patients optimize their medications to improve their quality of life and save money. Contact us for assistance.
